AJMC July 21, 2022
Randall A. Oyer, MD, medical director of the Ann B. Barshinger Cancer Institute, medical director of oncology, and medical director of the Cancer Risk Evaluation Program, Lancaster General Health, discusses recommendations to improve diversity in clinical trials.
The theme of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting was “Advancing Equitable Cancer Care Through Innovation.”
Randall A. Oyer, MD, medical director of the Ann B. Barshinger Cancer Institute, medical director of oncology, and medical director of the Cancer Risk Evaluation Program at Lancaster General Health in Pennsylvania, talked to Evidence-Based Oncology® (EBO) about the recent ASCO/Association of Community Cancer Centers (ACCC) recommendations for improving diversity in clinical trials, which also were discussed at the meeting.
Oyer is lead...
Today's Sponsors
Today's Sponsor